A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III

RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing
endometrial disorder in patients with breast cancer who are taking tamoxifen.

PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in
preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ,
lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II
breast cancer and who are taking tamoxifen.